Source-grounded facts extracted from Syndax Pharmaceuticals Inc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Syndax Pharmaceuticals Inc reported first quarter ended March 31, 2026 results: revenue Total revenue of $64.9 million.
“Syndax Reports First Quarter 2026 Financial Results and Provides Business Update • Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – • Revuforj ® (revumenib) net revenue of $48.9 million in 1Q26”
Syndax Pharmaceuticals Inc: Amended bylaws to provide that shares of capital stock shall be issued solely in uncertificated form starting December 18, 2025, with existing certificated shares remaining in certificated form until surrendered (effective 2025-12-18).
“On December 18, 2025, the Board of Directors of Syndax Pharmaceuticals Inc. (the “ Company ”) approved amendments to the Amended and Restated Bylaws (the “ Bylaws ”) of the Company, effective on such date. The amendments to the Bylaws provide that, beginning on December 18, 2025, shares of the Company’s capital stock shall be issued solely in uncertificated form; however, shares represented by a certificate issued prior to December 18, 2025 shall remain in certificated form until such certificate is surrendered to the Company.”
Neil Gallagher resigned as President, Head of Research and Development at Syndax Pharmaceuticals Inc.
“Neil Gallagher, M.D. Ph.D, President, Head of Research and Development of the Company, notified the Company of his intention to resign from his position as President, Head of Research and Development.”
Nicholas A.J. Botwood was appointed as Head of Research and Development, Chief Medical Officer at Syndax Pharmaceuticals Inc.
“Nicholas A.J. Botwood, BSC (HONS), MB BS, MFPM, FRCP, will join the Company as Head of Research and Development, Chief Medical Officer, effective May 12, 2025.”
Syndax Pharmaceuticals Inc shareholders approved Ratification of selection of independent registered public accounting firm at the 2024-05-15 meeting.
“Proposal 3 : Ratification of selection of independent registered public accounting firm: For Against Abstain Broker Non-Votes 65,371,337 253,270 21,499 —”
Syndax Pharmaceuticals Inc shareholders approved Advisory vote on executive compensation at the 2024-05-15 meeting.
“Proposal 2 : Advisory vote on executive compensation: For Against Abstain Broker Non-Votes 46,228,421 16,304,796 80,119 3,032,770”
Syndax Pharmaceuticals Inc shareholders approved Election of directors at the 2024-05-15 meeting.
“Proposal 1 : Election of directors: Nominee For Withheld Broker Non-Votes Martin H. Huber, M.D. 61,876,711 736,625 3,032,770”
Briggs W. Morrison resigned as Director at Syndax Pharmaceuticals Inc.
“On May 14, 2024, Briggs W. Morrison, M.D. advised the Board that he will resign from his position as a Class III member of our Board effective immediately.”
Aleksandra Rizo was elected as Director at Syndax Pharmaceuticals Inc.
“On May 15, 2024, the Board of Directors (the “ Board ”) of Syndax Pharmaceuticals, Inc. (the “ Company ”), unanimously voted to elect Aleksandra Rizo, M.D., Ph.D. to the Board, effectively immediately”
Syndax Pharmaceuticals Inc reported the quarter ended March 31, 2024 results: net income net loss attributable to common stockholders of $72.4 million, EPS $0.85 per share.
“Syndax reported a net loss attributable to common stockholders of $72.4 million, or $0.85 per share, compared to a net loss attributable to common stockholders of $41.1 million, or $0.59 per share, for the comparable prior year period”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.